Reference

1. ^Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W, Stoehr N, Stein T, Gasparini F, Vranesic I, Kuhn R, Nicoletti F, Flor PJ (2003).„(-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection”.Neuropharmacology.45 (7): 895—906.PMID 14573382.doi:10.1016/S0028-3908(03)00271-5. 
2. ^Beqollari D, Kammermeier PJ (2008). „The mGlu(4) receptor allosteric modulator N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide acts as a direct agonist at mGlu(6) receptors”.European Journal of Pharmacology.589 (1–3): 49—52.PMID 18593581.doi:10.1016/j.ejphar.2008.06.054. 
3. ^Stachowicz K, Kłak K, Kłodzińska A, Chojnacka-Wojcik E, Pilc A (2004). „Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats”.European Journal of Pharmacology.498 (1–3): 153—6.PMID 15363989.doi:10.1016/j.ejphar.2004.07.001. 
4. ^Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, Rodriguez AL, Marlo JE, de Paulis T, Thompson AD, Days EL, Nalywajko T, Austin CA, Williams MB, Ayala JE, Williams R, Lindsley CW, Conn PJ (2008).„Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4”.Molecular Pharmacology.74 (5): 1345—58.PMC 2574552 .PMID 18664603.doi:10.1124/mol.108.049551. 

Vidi još

Spoljašnje veze